The KRT20 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the CAL-27 human tongue squamous cell carcinoma line, engineered for targeted disruption of the KRT20 gene. This product serves as a versatile loss-of-function model for investigating keratin intermediate filament biology in an epithelial malignancy context. The polyclonal population, generated through CRISPR/Cas9-mediated gene disruption, includes a spectrum of edited alleles, providing a robust tool for functional genomics without clonal selection. Researchers can employ this model to dissect KRT20-dependent cellular processes in a background that retains the malignant features of oral squamous cell carcinoma.
CAL-27 cells originate from a 56-year-old male patient with squamous cell carcinoma of the tongue and are widely used as a representative model for oral squamous cell carcinoma research. These adherent epithelial cells exhibit malignant behaviors, including dysregulated proliferation, migration, and invasion, making them an appropriate host for interrogating cytoskeletal and adhesion pathways. By introducing a KRT20 disruption in this clinically relevant line, the product enables studies that directly connect keratin biology to oral cancer pathogenesis. The parental CAL-27 line’s well-characterized mutational landscape and sensitivity to various pharmacologic agents further enhance its utility as an experimental platform.
KRT20 encodes a type I intermediate filament protein that predominantly heterodimerizes with Keratin 8 (KRT8) to form the cytoskeletal network in differentiated epithelial cells. This keratin pair is integral to maintaining mechanical integrity, cell shape, and desmosomal adhesion. In this knockout model, disruption of KRT20 alters the stoichiometry of KRT8-KRT20 filaments, leading to compensatory shifts in keratin network composition and desmoplakin redistribution. The loss of KRT20 can also influence epithelial-to-mesenchymal transition (EMT) markers, including upregulation of vimentin and downregulation of E-cadherin, thereby modulating migratory and invasive potential. Upstream, KRT20 expression is regulated by transcription factors such as CDX2 and GATA6, as well as retinoic acid signaling and epigenetic modifiers. At the protein level, KRT20 interacts with desmosomal components like desmoplakin and plakoglobin, linking intermediate filaments to intercellular junctions and focal adhesions. Thus, KRT20 disruption serves as a molecular switch affecting cytoskeletal architecture and adhesion complexes.
In the CAL-27 background, KRT20 knockout provides a disease-relevant system to explore how keratin filament perturbations contribute to oral squamous cell carcinoma progression. As KRT20 is often differentially expressed in various carcinomas, including colorectal and urothelial cancers, this model may also offer translational insights beyond oral oncology. The polyclonal population allows interrogation of heterogeneous knockout effects, which may better reflect tumor heterogeneity compared to clonal isolates. Researchers can use these cells to examine how loss of an intermediate filament protein reconfigures the cytoskeleton, alters cell adhesion, and promotes an EMT-like phenotype, all critical features in cancer metastasis and therapeutic resistance.
Typical applications include mechanistic studies of keratin-dependent signaling in oral squamous cell carcinoma, screens for compounds that disrupt or stabilize intermediate filaments, and quantitative assays of cell migration and invasion. Recommended experimental techniques encompass immunofluorescence staining to visualize keratin network reorganization and desmoplakin localization, western blotting for KRT20, KRT8, vimentin, and E-cadherin, as well as functional assays such as wound healing, transwell invasion, and cell adhesion measurements. Phalloidin staining for filamentous actin and RT-qPCR analysis of EMT markers can complement these approaches to provide a comprehensive assessment of cytoskeletal dynamics and phenotypic shifts. These applications make the KRT20 Knockout CAL-27 Polyclonal Cells an essential resource for cancer cell biologists and drug discovery programs. For additional details or technical support, please contact Ascent Research.
